$68.86-0.86 (-1.23%)
GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. in the Healthcare sector is trading at $68.86 with a market capitalization of $33.3B. Wall Street consensus targets $82.50 (18 analysts), implying a +19.8% move over the next 12 months. The stock is currently 23% below its 52-week high of $89.77, remaining 5.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.29B↑ | $5.13B↓ | $5.70B↑ | $5.14B↑ | $5.01B |
| Gross Profit | $2.18B↑ | $1.98B↓ | $2.26B↑ | $1.99B↑ | $1.98B |
| Operating Income | $738.00M↑ | $515.00M↓ | $827.00M↑ | $653.00M↑ | $652.00M |
| Net Income | $560.00M↑ | $389.00M↓ | $589.00M↑ | $446.00M↓ | $486.00M |
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internati...

GE HealthCare Technologies has slipped year to date, yet on broad valuation checks the stock still screens as relatively cheap compared with its fundamentals. Investors are weighing that disconnect against a steady stream of product developments in imaging and cardiology. Year to date, GE HealthCare Technologies is down 14.8%, which may make the current share price more interesting for value focused investors who already follow the company. Progress in advanced imaging such as the Photonova...

GE HealthCare's Photonova Spectra gains CE Mark, expanding access to its Deep Silicon photon-counting CT technology across Europe and other CE markets.

On August 31, GE HealthCare (NASDAQ:GEHC) announced that its Photonova Spectra photon-counting CT scanner had received CE Mark approval, opening the door to sales across Europe and other regions that recognize the certification. The clearance followed US FDA 510(k) clearance and Japanese regulatory approval in March 2026, meaning the machine cleared three major regulatory bodies […]

Photonova Spectra is designed to deliver ultra-high definition and on-demand spectral and spatial imaging.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Academic risk and quality models computed from GEHC's own filings and price history, not from analyst opinion.
Mixed: 4 of 9 fundamental-health tests pass, so profitability and balance-sheet trends disagree.
Altman Z in the 1.81 to 2.99 grey zone, the band where the model gives no clear bankruptcy verdict.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.